{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:16:41Z","timestamp":1793031401247,"version":"4.5.0"},"reference-count":65,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012895","name":"Zoetis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Apoquel(oclacitinib maleate) as a film\u2010coated tablet, a selective Janus kinase (JAK)1 inhibitor, was approved by the United States Food and Drug Administration (FDA) in 2013 for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12\u2009months of age. The goal of this review is to describe the safety of oclacitinib in dogs based on data from investigational laboratory and field studies, independent directed studies, and an extensive postmarketing pharmacovigilance (PV) surveillance program. The safety of oclacitinib has been extensively evaluated in investigational and independent studies. In the oclacitinib postapproval PV surveillance, the types and rank order of frequency of reported adverse events were similar to the premarketing field studies, with diarrhea, anorexia, and lethargy being the most frequently reported adverse events. In the postmarketing PV continuous monitoring, adverse events for patients receiving oclacitinib are rarely reported and the individual clinical signs within the PV adverse event reports were considered \u201cvery rare\u201d in frequency. An age\u2010 and breed\u2010 matched retrospective cohort study in dogs with allergic dermatitis showed no significant difference in incidence of neoplasia between dogs treated with oclacitinib and dogs treated with other systemic therapies. The extensive investigational and PV experience with oclacitinib shows that long\u2010term or lifelong use per label instructions has a positive benefit\u2013risk profile and is not associated with any cumulative safety risk.<\/jats:p>","DOI":"10.1111\/jvp.13503","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T11:13:06Z","timestamp":1741691586000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety of the Selective\n                    <scp>JAK1<\/scp>\n                    Inhibitor Oclacitinib in Dogs"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0663-4602","authenticated-orcid":false,"given":"Steven M.","family":"Nederveld","sequence":"first","affiliation":[{"name":"Zoetis  Parsippany\u2010Troy Hills New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Krautmann","sequence":"additional","affiliation":[{"name":"Zoetis (Retired)  Parsippany\u2010Troy Hills New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Zoetis  Parsippany\u2010Troy Hills New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"American Veterinary Medical Association. n.d.\u201cMore Itchy Pets? No Problem. More Treatments Available Alongside Increasing Incidence or Awareness of Itchy Dogs and Cats.\u201dAccessed November 25 2023.https:\/\/www.avma.org\/javma\u2010news\/2020\u201002\u201015\/more\u2010itchy\u2010pets\u2010no\u2010problem."},{"key":"e_1_2_13_3_1","volume-title":"AVMA Pet Ownership and Demographics Sourcebook","author":"American Veterinary Medical Association","year":"2017"},{"key":"e_1_2_13_4_1","unstructured":"Barron's. n.d.\u201cZoetis Reports Solid Results and Boosts Outlook as Pandemic Puts Pets in Focus.\u201dAccessed January 4 2023.https:\/\/www.barrons.com\/articles\/zoetis\u2010reports\u2010solid\u2010results\u2010and\u2010boosts\u2010outlook\u2010as\u2010pandemic\u2010puts\u2010pets\u2010in\u2010focus\u201051604590794?reflink=desktopwebshare_permalink."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.012"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.108"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12087"},{"issue":"1","key":"e_1_2_13_8_1","first-page":"38","article-title":"A Multicentre Clinical Trial to Evaluate the Efficacy and Field Safety of Oclacitinib (Abstract)","volume":"23","author":"Cosgrove S.","year":"2012","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12194"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12047"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12088"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12047"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12047"},{"key":"e_1_2_13_14_1","unstructured":"Elanco. n.d.\u201cZenrelia Product Information Zenrelia (Ilunocitinib Tablets) Product Information.\u201dAccessed December 11 2024."},{"key":"e_1_2_13_15_1","unstructured":"European Commission.2009.\u201cA Guideline on Summary of Product Characteristics (SmPC).\u201dAccessed: December 17 2023.https:\/\/health.ec.europa.eu\/system\/files\/2016\u201011\/smpc_guideline_rev2_en_0.pdf."},{"key":"e_1_2_13_16_1","unstructured":"European Commission. n.d.\u201cPharmacovigilance.\u201dAccessed December 17 2023.https:\/\/health.ec.europa.eu\/medicinal\u2010products\/pharmacovigilance_en."},{"key":"e_1_2_13_17_1","unstructured":"European Medicines Agency.2013.\u201cVich Gl24 on Pharmacovigilance of Veterinary Medicinal Products: Management of Adverse Event Reports (AERs).\u201dAccessed December 17 2023.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/vich\u2010gl24\u2010guideline\u2010pharmacovigilance\u2010veterinary\u2010medicinal\u2010products\u2010management\u2010adverse\u2010event\u2010reports\u2010aers_en.pdf."},{"key":"e_1_2_13_18_1","unstructured":"European Medicines Agency.2023.\u201cGuidance Notes on the Use of Veddra Terminology for Reporting Suspected Adverse Events in Animals and Humans (2023).\u201dAccessed December 17 2023.https:\/\/www.ema.europa.eu\/en\/documents\/regulatory\u2010procedural\u2010guideline\/guidance\u2010notes\u2010use\u2010veterinary\u2010dictionary\u2010drug\u2010regulatory\u2010activities\u2010veddra\u2010terminology\u2010reporting\u2010suspected\u2010adverse\u2010events\u2010animals\u2010and\u2010humans_en.pdf."},{"key":"e_1_2_13_19_1","unstructured":"European Medicine Agency. n.d.\u201cEMA Pharmacovigilance System Manual.\u201dAccessed December 26 2023.https:\/\/www.ema.europa.eu\/system\/files\/documents\/other\/ema_pharmacovigilance_system_manual_march21\u2010en.pdf."},{"key":"e_1_2_13_20_1","unstructured":"European Medicines Agency. n.d.\u2010a.\u201cApoquel (oclacitinib) European Public Assessment Report (EPAR) Annex 1 Summary of Product Characteristics.\u201dAccessed November 25 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/apoquel\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_13_21_1","unstructured":"European Medicines Agency. n.d.\u2010b.\u201cCombined VeDDRA List of Clinical Terms for Reporting Suspected Adverse Events in Animals and Humans to Veterinary Medicinal Products.\u201dAccessed January 20 2024.https:\/\/www.ema.europa.eu\/en\/documents\/regulatory\u2010procedural\u2010guideline\/combined\u2010veterinary\u2010dictionary\u2010drug\u2010regulatory\u2010activities\u2010veddra\u2010list\u2010clinical\u2010terms\u2010reporting\u2010suspected\u2010adverse\u2010events\u2010animals\u2010and\u2010humans\u2010veterinary\u2010medicinal\u2010products_en.pdf."},{"key":"e_1_2_13_22_1","unstructured":"European Medicines Agency. n.d.\u2010c.\u201cAnnex I: Summary of Product Characteristics Template (Version 9 03\/2022 Corr. 11\/2022).\u201dAccessed January 26 2024.https:\/\/www.ema.europa.eu\/en\/documents\/template\u2010form\/qrd\u2010veterinary\u2010product\u2010information\u2010annotated\u2010template\u2010english\u2010version\u201090_en.pdf."},{"key":"e_1_2_13_23_1","unstructured":"European Medicines Agency. n.d.\u2010d.\u201cEudravigilance\u2014European Database of Suspected Adverse Drug Reaction Reports.\u201dAccessed: February 5 2024.https:\/\/www.adrreports.eu\/vet\/en\/index.html."},{"key":"e_1_2_13_24_1","unstructured":"FDA. n.d.\u201cDear Veterinarian Letter Regarding Important Safety Information Associated With the Use of Zenrelia (Ilunocitinib Tablets) for Controlling Pruritus Associated With Allergic Dermatitis and Atopic Dermatitis in Dogs.\u201dAccessed December 11 2024."},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12166"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12101"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01098.x"},{"issue":"7","key":"e_1_2_13_28_1","first-page":"208","article-title":"Efficacy of Apoquel for the Control of Otitis Externa Secondary to Allergic Skin Disease in Client\u2010Owner Dogs","volume":"5","author":"Gotthelf L.","year":"2017","journal-title":"International Journal of Veterinary Health Science & Research"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.8.743.36068"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2427(01)00296-3"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0150-2"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.1985.186.01.43"},{"issue":"4","key":"e_1_2_13_34_1","first-page":"252","article-title":"A Six Years Global Pharmacovigilance Review of Suspected Adverse Reactions From Oclacitinib in Dogs: 1 January 2016 to 31 December 2021 (Abstract)","volume":"34","author":"Khan S.","year":"2023","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.257.5.507"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12186"},{"key":"e_1_2_13_37_1","unstructured":"Malpas P. B. R. K.Frank V. L.King W. T.Collard G. E.Gagnon andM. R.Stegemann.2013.\u201cMargin of Safety Study of Oclacitinib Maleate Administered to Adult Laboratory Dogs for 26\u2009Weeks at Multiples of the Therapeutic Dose. Proceedings of the 18th American Academy of Veterinary Pharmacology and Therapeutics Biennial Symposium.\u201d"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.22.12.0570"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.241.2.194"},{"key":"e_1_2_13_40_1","unstructured":"Nationwide Mutual Insurace Company. n.d.\u201cDermatitis Otitis Externa Continue to Top Common Conditions That Prompt Veterinary Visits.\u201dAccessed November 25 2023.https:\/\/news.nationwide.com\/dermatitis\u2010otitis\u2010externa\u2010top\u2010common\u2010conditions\u2010vet\u2010visits\/."},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-44605-8_19"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2010.00889.x"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3164.2003.00335.x"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01044.x"},{"key":"e_1_2_13_45_1","first-page":"389","article-title":"Oclacitinib (Apoquel) Inhibits Allergen\u2010Induced Production of Interleukin\u201031 but Not Interferon\u2010c or Interleukin\u20104 in Canine Th2 Cells (Abstract)","volume":"25","author":"Rugg C. A.","year":"2014","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043391"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12450"},{"key":"e_1_2_13_48_1","unstructured":"StatPearls Publishing.\u201cDrug Labeling.\u201dAccessed: December 17 2023.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557743\/."},{"key":"e_1_2_13_49_1","unstructured":"The European Agency for the Evaluation of Medicinal Products (Veterinary Medicines and Inspections).\u201cGuideline on Procedures for Competent Authorities for Pharmacovigilance Information for Veterinary Medicinal Products (EMEA\/CVMP\/345\/98\u2010Rev.1\u2010Final).\u201dupdated 2004."},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2005.227.239"},{"key":"e_1_2_13_51_1","unstructured":"U.S. Food and Drug Administration.2013.\u201cApoquel (Oclacitinib Tablet) Prescribing Information.\u201d"},{"key":"e_1_2_13_52_1","unstructured":"U.S. Food and Drug Administration.2023.\u201cApoquel Chewable (Oclacitinib Chewable Tablet) Prescribing Information.\u201dhttps:\/\/www.zoetisus.com\/content\/pages\/Products\/Dogs\/Apoquel\u2010Resources\/documents\/apoquel_chewable_prescribing_information.pdf."},{"key":"e_1_2_13_53_1","unstructured":"U.S. Food and Drug Administration.2024.\u201cZenrelia (Ilunocitinib Tablets) Prescribing Information.\u201dhttps:\/\/assets\u2010us\u201001.kc\u2010usercontent.com\/e4748d51\u20102c24\u201000f7\u2010fc54\u201065f3864ee8b1\/9430d8ce\u2010848d\u2010461c\u201088a3\u2010c328a81274e6\/PROMO_WEB_104098As_PA104098X_W2a_WS.pdf."},{"key":"e_1_2_13_54_1","unstructured":"U.S. Food and Drug Administration. n.d.\u2010a.\u201cAtopica (Cyclosporine Capsules) Prescribing Information.\u201dAccessed November 25 2023.https:\/\/www.elancolabels.com\/us\/atopica\u2010dogs."},{"key":"e_1_2_13_55_1","unstructured":"U.S. Food and Drug Administration. n.d.\u2010b.\u201cApoquel (Oclacitinib Tablet) Prescribing Information (Updated 2020).\u201dAccessed November 25 2023.https:\/\/www.zoetisus.com\/content\/pages\/products\/dogs\/Apoquel\u2010Resources\/documents\/apoquel_prescribing_information.pdf."},{"key":"e_1_2_13_56_1","unstructured":"U.S. Food and Drug Administration. n.d.\u2010c.\u201cFreedom of Information Summary Original New Animal Drug Application. Apoquel (Oclacitinib Tablet) for Dogs.\u201dAccessed November 25 2023.https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/902."},{"key":"e_1_2_13_57_1","unstructured":"U.S. Food and Drug Administration. n.d.\u2010d.\u201cOpenFDA.\u201dAccessed February 5 2024.https:\/\/open.fda.gov\/apis\/."},{"key":"e_1_2_13_58_1","unstructured":"U.S. Food and Drug Administration.\u201cCvm Gfi #117 (Vich Gl24) Management of Adverse Event Reports (AER's).\u201dAccessed: December 26 2023.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/cvm\u2010gfi\u2010117\u2010vich\u2010gl24\u2010management\u2010adverse\u2010event\u2010reports\u2010aers."},{"key":"e_1_2_13_59_1","unstructured":"U.S. Food and Drug Administration. n.d.\u2010e.\u201cGuidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment.\u201dAccessed: December 26 2023.https:\/\/www.fda.gov\/media\/71546\/download."},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-010-9772-7_2"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444322958"},{"key":"e_1_2_13_62_1","unstructured":"World Organisation for Animal Health. n.d.\u201cHow to Set up a Pharmacovigilance System for Veterinary Medicinal Products.\u201dAccessed: January 4 2023.https:\/\/www.woah.org\/app\/uploads\/2023\/02\/af\u2010bookfarmavet\u2010v90223\u2010ang.pdf."},{"key":"e_1_2_13_63_1","unstructured":"Zoetis. n.d.\u2010a.\u201cZoetis Celebrates 10\u2009Years of Apoquel and Innovation in Dermatology.\u201dAccessed November 25 2023.https:\/\/www.zoetisus.com\/news\u2010and\u2010media\/zoetis\u2010celebrates\u201010\u2010years\u2010of\u2010apoquel\u2010and\u2010innovation\u2010in\u2010dermatology."},{"key":"e_1_2_13_64_1","unstructured":"Zoetis. n.d.\u2010b.\u201cApoquel Technical Summary (Data on File).\u201d"},{"key":"e_1_2_13_65_1","unstructured":"Zoetis. n.d.\u2010c.\u201cOclacitinib (Apoquel) Pharmacovigilance Database (Data on File).\u201d"},{"key":"e_1_2_13_66_1","unstructured":"Zoetis. n.d.\u2010d.\u201cKynetec PetTrak\u2014GAH\u2010284 Unique Patient Count Since Launch Custom Report: Apoquel: January 2014\u2014February 2024 (Data on File).\u201d"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.13503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T01:25:49Z","timestamp":1747013149000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.13503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/jvp.13503"],"URL":"https:\/\/doi.org\/10.1111\/jvp.13503","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"2024-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}